Request Demo

Last update 19 Jul 2025

Etodolac

Last update 19 Jul 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid, (±)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid

+ [20]

Target

COX-2

Action

inhibitors

Mechanism

COX-2 inhibitors(Cyclooxygenase-2 inhibitors)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [4]

Active Indication

OsteoarthritisRheumatoid ArthritisAnalgesia+ [4]

Inactive Indication-

Originator Organization

Pfizer Inc.

Active Organization

Nippon Shinyaku Co., Ltd.

Hamamatsu University School of Medicine

ASKA Pharmaceutical Co., Ltd.

+ [1]

Inactive Organization

Wyeth Pharmaceuticals LLC

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (31 Jan 1991),

OsteoarthritisPain

Regulation-

Structure/Sequence

Molecular FormulaC17H21NO3

InChIKeyNNYBQONXHNTVIJ-UHFFFAOYSA-N

CAS Registry41340-25-4

Clinical Trials associated with Etodolac

NCT05429970

/ RecruitingNot ApplicableIIT

Perioperative Stress Reduction in Ovarian Cancer (PRESERVE Trial)-A Prospective Randomized Pilot Study

The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery/PDS or IDS and also if it's better than the standard-of-care approach (no intervention for reducing stress).

Start Date17 Jun 2022

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

ChiCTR2100046838

/ RecruitingEarly Phase 1IIT

Lodine bioavailability from different sources of dietary iodine intake in human trail derived from dietary iodine reference intake research for young adults

Start Date12 May 2021

Sponsor / Collaborator-

CTR20190145

/ CompletedNot Applicable

依托度酸胶囊空腹及餐后人体生物等效性研究

[Translation] Study on the bioequivalence of etodolac capsules in fasting and fed subjects

以山东新时代药业有限公司生产的依托度酸胶囊（规格：0.2g）为受试制剂，Taro Pharmaceutical Industries Ltd.生产的依托度酸胶囊（规格：200mg）为参比制剂，考察两制剂在空腹及餐后状态下单次给药吸收速度和程度的差异，评价两制剂是否生物等效。

[Translation]

Etodolac capsules (specification: 0.2 g) produced by Shandong Xinshidai Pharmaceutical Co., Ltd. were used as the test preparation, and etodolac capsules (specification: 200 mg) produced by Taro Pharmaceutical Industries Ltd. were used as the reference preparation. The differences in the absorption rate and extent of single administration of the two preparations in the fasting and postprandial states were investigated to evaluate whether the two preparations were bioequivalent.

Start Date08 Apr 2019

Sponsor / Collaborator

Shandong New Time Pharmaceutical Co. Ltd.

100 Clinical Results associated with Etodolac

100 Translational Medicine associated with Etodolac

100 Patents (Medical) associated with Etodolac

1,724

Literatures (Medical) associated with Etodolac

01 Aug 2025·COLLOIDS AND SURFACES B-BIOINTERFACES

Enhanced skin adhesion of transdermal drug delivery system a semi-IPN strategy: / evaluation and drug release mechanism

Article

Author: Zhang, Yimeng ; Li, Maojian ; Zhao, Nanxi ; Xie, Daoxuan ; Luo, Zheng ; Chen, Guixue ; Liu, Yanan ; Li, Man

Pressure-sensitive adhesives (PSAs) used for transdermal patches often present mechanical issues that lead to cold flow phenomena, patch shifting, and disrupt dose precision while creating an unwanted "dark ring" effect. Semi-interpenetrating network (semi-IPN) PSAs were synthesized in this study, which enhanced cohesion and reduced cold flow by integrating a cross-linked network into a linear polymer matrix to enhance structural integrity. Meanwhile, rivastigmine, etodolac, ketoprofen, propranolol, pirfenidone, and zolmitriptan were used to evaluate drug release rates from the semi-IPN PSA. The skin adhesion properties of the semi-IPN PSA were outstanding. Its cohesion was significantly higher than two commercially available PSAs: over 1000-fold greater than DURO-TAK® 87-2287 and 75.9 times greater than DURO-TAK® 87-4098. Drug release rates were comparable between traditional and semi-IPN PSAs. The release rates of different drugs were negatively correlated with drug polarizability, suggesting dipole-dipole interactions as the key mechanism. In summary, the semi-IPN strategy offers a robust solution for high-performance transdermal patches by improving adhesion without compromising drug release.

01 Jul 2025·BIOORGANIC CHEMISTRY

Novel chalcone candidates as potential in vitro and in vivo anti-inflammatory agents: Synthesis, in silico docking, multitarget bioevaluation and molecular dynamic simulation

Article

Author: Mohamed, Mamdouh F A ; Beshr, Eman A M ; Salem, Ibrahim M ; Ahmed, Alshimaa Kh M ; Elsayed Abouzed, Deiaa E ; Ibrahim, Tarek S ; Mahmoud, Ahmed Mostafa ; Ahmed, Osama A A

Managing inflammation with the commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) represents a critical challenge in modern medicine because of its strong influence on the cyclooxygenase-1 (COX-1) enzyme might induce substantial adverse effects. Therefore, there is urgent necessity for the exploration of safer alternatives, particularly cyclooxygenase-2 (COX-2) inhibitors. This study aimed to address this issue through the synthesis and evaluation of 19 new chalcone derivatives (2a-m and 4a-f) for their in vitro anti-inflammatory activity against various biotargets including iNOS, COX-2, 5-LOX, PGE2, and TNFα. Moreover, these compounds showed moderate to strong anti-inflammatory activity in the carrageenan rat paw edema test. Compounds 2a, 2f, 2 h, 2 m, and 4b are promising candidates for the treatment of inflammatory diseases. In particular, compound 4b was demonstrated to be the most effective derivative as a nitric oxide release inhibitor, exhibiting a 61.7 % inhibition rate. It exhibited substantial selectivity for COX-2 (IC₅₀ = 1.933 μM) compared to COX-1 (IC₅₀ = 5.526 μM). Compound 4b exhibited notable inhibitory activity against 5-LOX (IC₅₀ = 2.112 μM) and demonstrated considerable inhibitory activity against iNOS, PGE2, and TNF-α biotargets in LPS-stimulated RAW cells, with IC₅₀ values of 114.18, 37.13, and 58.15 nM, respectively. The in vivo anti-inflammatory effects demonstrated the significant efficacy of compound 4b, as evidenced by a notable edema inhibition rate of 37.05 %, along with minimal ulcerogenic activity observed in the histopathological findings. In silico experiments demonstrated that the intermolecular contacts of the most active chemical 4b with the biotargets COX-2, 5-LOX, and iNOS were analyzed by docking, revealing significant binding interactions. The stability of the interactions between compound 4b and the targets COX-2, 5-LOX, and iNOS was assessed using a standard 100 ns atomistic dynamic simulation method. Various parameters derived from MD simulation trajectories were adjusted and validated to confirm the stability of the generated complexes under dynamic settings. Ultimately, compound 4b exhibited favorable physicochemical properties and satisfactory drug-likeness, indicating its potential as an oral anti-inflammatory agent, warranting additional structure-activity relationship investigation and optimization.

05 Jun 2025·Nature

C-to-N atom swapping and skeletal editing in indoles and benzofurans

Article

Author: Studer, Armido ; Wang, Zhe ; Xu, Pengwei ; Daniliuc, Constantin G ; Guo, Shu-Min

Abstract:

Skeletal editing comprises the structural reorganization of compounds. Such editing can be achieved through atom swapping, atom insertion, atom deletion or reorganization of the compound’s backbone structure1,2. Conducted at a late stage in drug development campaigns, skeletal editing enables diversification of an existing pharmacophore, enhancing the efficiency of drug development. Instead of constructing a heteroarene classically from basic building blocks, structural variants are readily accessible directly starting from a lead compound or approved pharmacophore. Here we present C to N atom swapping in indoles at the C2 position to give indazoles through oxidative cleavage of the indole heteroarene core and subsequent ring closure. Reactions proceed through ring-opened oximes as intermediates. These ring deconstructed intermediates can also be diverted into benzimidazoles resulting in an overall C to N atom swapping with concomitant skeletal reorganization. The same structural diverting strategies are equally well applicable to benzofurans leading to either benzisoxazoles or benzoxazoles. The compound classes obtained through these methods—indazoles3,4, benzisoxazoles5, benzimidazoles6,7 and benzoxazoles8—are biologically relevant moieties found as substructures in natural products and pharmaceuticals. The procedures introduced substantially enlarge the methods portfolio in the emerging field of skeletal editing.

News (Medical) associated with Etodolac

15 Nov 2021

·www.biospace.com

Bayshore Pharmaceuticals Announces Commercial Launch of ANDA Approved Products

Nov. 15, 2021 11:00 UTC SHORT HILLS, N.J.--(BUSINESS WIRE)-- Bayshore Pharmaceuticals, LLC is pleased to introduce three new FDA-approved products to their expanding portfolio. Metolazone Tablets USP, 2.5mg, 5mg and 10 mg, is the generic equivalent of Zaroxolyn Tablets. It is available by prescription only and is indicated for the treatment of high blood pressure and fluid retention. Etodolac Immediate Release Tablets USP, 400 mg and 500 mg, is the generic equivalent of Lodine Tablets. Etodolac is a nonsteroidal anti-inflammatory drug and only available by prescription. Ketotifen Fumarate Ophthalmic Solution, 0.035% (OTC & RX) is the generic equivalent of Zaditor. It is an antihistamine that is indicated for the treatment of itchy eyes. Ketotifen is Bayshore Pharmaceutical’s first ANDA approved product that is available by prescription or as an OTC in the Bayshore Label. “Bayshore is very proud to bring these internal R&D projects through to FDA approval and commercialization. These efforts further exemplify our focus on balancing internally developed products with our continued partnerships with manufacturing partners such as Beximco Pharmaceuticals, in which we can utilize our trade relationships to market & distribute ANDA’s for those companies not set up do so directly,” says Mark Moshier, President of Bayshore Pharmaceuticals. About Bayshore Pharmaceuticals: Bayshore Pharmaceuticals, LLC was established in 2011 in the centrally located area of Short Hills, NJ. As a full-service Sales & Distribution company focusing on FDA-approved generic pharmaceuticals, Bayshore used its extensive knowledge and experience in global API and Finished Dosage Form manufacturing to differentiate itself from other Generic Pharmaceutical Sales & Marketing organizations. In addition to developing its wholly-owned portfolio of generic products, Bayshore successfully utilized its longstanding industry relationships to augment its business by marketing other pharma manufacturer’s ANDA products under the same Bayshore label. With a strong emphasis on Project Management and Supplier & Customer transparency, Bayshore, along with our global manufacturing partners, maintains the highest level of product quality, in full compliance with current Good Manufacturing Practices (cGMP). This mission has allowed Bayshore to become one of the most service-oriented and reliable supply partners in the industry. View source version on businesswire.com: Contacts Mark Moshier, President (973) 315-1819 Dena Mando, Vice President Sales & Marketing (973) 315-1824 Source: Bayshore Pharmaceuticals View this news release online at:

04 Oct 2021

·endpts.com

Three generic firms shell out $447M more to settle federal price fixing allegations

Generic drug firms Taro Pharmaceuticals USA, Novartis’ Sandoz, and Apotex have agreed with the US Department of Justice to pay $447.2 million on top of the more than $400 million in criminal penalties they already paid to resolve alleged violations that they illegally collaborated on price, supply and allocation of customers with other pharma manufacturers. Each of the companies entered a five-year corporate integrity agreement, which includes internal monitoring and price transparency provisions, among other checks and balances. New York-based Taro will pay almost half of that latest sum, or $213.2 million, for alleged violations involving the nonsteroidal drug etodolac, and nystatin-triamcinolone cream and ointment to treat skin infections. Sandoz agreed to pay $185 million related to alleged issues with benazepril HCTZ, used to treat hypertension, and clobetasol, a corticosteroid used to treat skin conditions. “The conduct at issue here occurred at Sandoz from March 2013 through December 2015 in direct contravention of the company’s values, policies and trainings in place at the time. The individuals implicated in the underlying conduct are no longer employed by the company,” Sandoz said in a statement. And Florida-based Apotex agreed to pay $49 million in connection with its sale of pravastatin, a drug used to treat high cholesterol and triglyceride levels. Apotex is also part of another ongoing investigation involving pravastatin price-fixing allegations, involving Teva Pharmaceuticals and Glenmark Pharmaceuticals. This latest $447 million payout also follows the payment of separate criminal penalties, in which Taro paid $205.6 million and admitted to conspiring with two other generic drug companies to fix prices on certain generic drugs, while Sandoz paid another $195 million and admitted to conspiring with four other generic drug companies to fix prices on certain generic drugs, and Apotex paid $24.1 million and admitted to conspiring to increase and maintain the price on pravastatin.

Generic DrugCollaborate

100 Deals associated with Etodolac

External Link

KEGG	Wiki	ATC	Drug Bank
D00315	Etodolac	M01AB08	DB00749

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Rheumatoid Arthritis	China	Wyeth-Ayerst Laboratories	22 Jun 1999
Analgesia	Japan	ASKA Pharmaceutical Co., Ltd.	01 Jul 1994
Inflammation	Japan	Nippon Shinyaku Co., Ltd.	01 Jul 1994
Inflammation	Japan	ASKA Pharmaceutical Co., Ltd.	01 Jul 1994
Osteoarthritis	United States	Wyeth Pharmaceuticals LLC	31 Jan 1991
Pain	United States	Wyeth Pharmaceuticals LLC	31 Jan 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Burkitt Lymphoma	Preclinical	Japan	Hamamatsu University School of Medicine	16 Nov 2005
Multiple Myeloma	Preclinical	Japan	Hamamatsu University School of Medicine	16 Nov 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis